Kanion Pharmaceutical(600557.SH)

Last Updated 00:00:00
longbridge loading

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

AASTOCKS·
SH
512290
-0.11%
SH
516500
-0.68%
SZ
159316
-0.98%
AASTOCKS·
SH
512290
-0.11%
SH
516500
-0.68%
SZ
159316
-0.98%

Kanion Pharmaceutical: Wholly-owned subsidiary's drug receives approval for additional indications

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%

A-share weight loss drug concept stocks continued to weaken in the afternoon, Menovo hit the limit down, Medicilon and Kanion Pharmaceutical fell over 7%, SDKX and HISOAR had the largest declines

Wallstreetcn·
SH
603538
+4.41%
SH
600557
-2.04%
SH
688136
-4.30%
Wallstreetcn·
SH
603538
+4.41%
SH
600557
-2.04%
SH
688136
-4.30%

The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declined

Wallstreetcn·
SZ
002873
-1.43%
SH
600557
-2.04%
SH
603087
+0.79%
Wallstreetcn·
SZ
002873
-1.43%
SH
600557
-2.04%
SH
603087
+0.79%

Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%

The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising

Zhitong·
SH
600572
-1.64%
SZ
300026
-1.50%
SZ
002166
+1.13%
Zhitong·
SH
600572
-1.64%
SZ
300026
-1.50%
SZ
002166
+1.13%

Kanion Pharmaceutical: Obtained the registration certificate for Canpu Granules

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%

Kanion Pharmaceutical received the clinical trial approval notice for KYS2301 gel

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%

Xiao Wei resigns as Chairman of Kanion Pharmaceutical, stepping back to "cultivate successors"

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%

Kanion Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%

Zhitong·
SH
600557
-2.04%
Zhitong·
SH
600557
-2.04%
© 2026 Longbridge｜Disclaimer